

Corinna Alisangco Gamez, M.D.
Pacific Research Partners, LLC.
901 Clay Street
Oakland, CA 94607

CONTACT INFORMATION:

Site Selection and Information:
Bobbie Theodore, Alliance Director
Tel. (916) 939-6696
Fax (208) 575-3169
Email: clinicaltrials@alliancesites.com

AFFILIATIONS:

Collaborative Neuroscience Network, LLC
12772 Valley View Street, Suite 3
Garden Grove, CA 92845

Collaborative Neuroscience Network, LLC
2600 Redondo Avenue, Suites 415 & 500
Long Beach, CA 90806

Collaborative Neuroscience Network, LLC
19401 S. Vermont Avenue, Suite F-100
Torrance, CA 90502

EDUCATION:

1987-1991 M.D., University of Santo Tomas, Manila, Philippines
1987 B.S., University of Santo Tomas, Manila, Philippines

INTERSHIPS and RESIDENCIES:

1999-2001 Fellow in Substance Abuse, San Francisco VAMC/UCSF, San Francisco, CA
1998-1999 Fellow in Consultation-Liaison Psychiatry, Harvard Longwood Program,
Brigham and Women's Hospital, Boston, MA/West Roxbury VAMC
1997-1998 Chief Resident and Fellow - Psychiatry in Primary Care (PRIME Fellow)
Harvard, South Shore Program, West Roxbury VAMC, W. Roxbury, MA
1996-1997 PGY-III Psychiatry, Harvard Medical School - South Shore Program
Brockton/W. Roxbury VAMC, Brockton, MA

INTERNSHIPS and RESIDENCIES (continued):

- 1995-1996 PGY-II Psychiatry, Harvard Medical School - South Shore Program
Brockton/W. Roxbury VAMC, Brockton, MA
- 1994-1995 PGY-I Psychiatry Internship, Harvard Medical School - South Shore
Program, Brockton/W. Roxbury VAMC
- 1992-1993 Externship in Internal Medicine, Santo Tomas University Hospital
Manila, Philippines
- 1991-1992 Rotating Internship, Santo Tomas University Hospital, Manila, Philippines

LICENSURE and CERTIFICATION:

Re-certified in General Psychiatry and Subspecialty in Addiction Psychiatry,
American Board of Psychiatry & Neurology, 2013
Certified in Subspecialty in Addiction Psychiatry, American Board of Psychiatry & Neurology, 2004
Diplomate, American Board of Psychiatry & Neurology, 2002
California State Medical License, 1999
Massachusetts State Medical License, 1996

PROFESSIONAL EXPERIENCE:

Investigator, October 2015 - present
Pacific Research Partners, LLC, Oakland, CA

Sub-Investigator, August 2014 - present
Pacific Research Partners, LLC, Oakland, CA

Medical Director, 2003 – Present
OBIC - Outpatient Buprenorphine Induction Clinic, UCSF/SFGH
San Francisco, CA

Associate Clinical Professor, 2002 – Present
UCSF, Department of Psychiatry, Division of Substance Abuse and Addiction Medicine San
Francisco General Hospital
San Francisco, CA

Medical Director, 2007 – May 2014
3 North McAuley Institute, Adolescent Day Treatment, St. Mary's Medical Center
San Francisco, CA

Attending Psychiatrist, 2004 – August 2013
5 North McAuley Institute, In-patient Psychiatric Unit, St. Mary's Medical Center
San Francisco, CA

PROFESSIONAL EXPERIENCE (continued):

Consultant Psychiatrist, 2004 – 2012

Asian Pacific Islander Wellness Center (API – HIV Focus Treatment)
San Francisco, CA

Medical Director, 2006 – 2008

Asian-American Recovery Services
San Francisco, CA

INVESTIGATOR EXPERIENCE:

Phase I • Addiction • Binge Eating Disorder • Bipolar Disorder • Depression • Fibromyalgia
Healthy • Migraine • Obsessive Compulsive Disorder • Opioid Use Disorder
Schizophrenia and Schizoaffective Disorder • Sexual Dysfunction
Smoking Cessation • Tardive Dyskinesia

CLINICAL TRIAL EXPERIENCE:

Phase I

A Phase Ib, Pivotal, Multiple-Dose, Pharmacokinetic Bioequivalence Trial Comparing Generic to Reference XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Patients with Schizophrenia or Schizoaffective Disorder

A Phase I, Randomized, Crossover, Open-Label, Multiple Dose, Pivotal Pharmacokinetic Bioequivalence Study Comparing XXX Extended-Release IM 156 mg/1 mL (100 mg eq) with XXX in Subjects with Schizophrenia or Schizoaffective Disorder

A Phase I, XXX Sub-study 002: Study of XXX and Android App Performance and Usability.

A Phase I, “RW2 Confirmatory Study” of the XXX system. The system is designed to enable mental health patients to measure and monitor their medication adherence as well as other information such as mood, rest, and activity.

A Phase I Randomized, Open-Label, Parallel Design, Multiple-Dose, Comparative Bioequivalence Study of XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) Versus XXX Extended-Release Injectable Suspension (156 mg/1.0 mL) in Schizophrenia Patients Already Stabilized on XXX

A Phase I, Randomized, Open-label, Single Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of XXX Following Administration to the Deltoid or Gluteal Muscle in Adults with Schizophrenia or Schizoaffective Disorder

A Phase I Study of XXX and XXX Co-administered with XXX in Adults with Schizophrenia

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase I, Reliability and validity of an online neurocognitive test battery, the XXX Test, in normal healthy adults

Addiction

A Phase III, Open-Label, Depot XXX Treatment Extension Study in Subjects With Opioid Use Disorder

A Phase III, Open-Label, Long-Term Safety and Tolerability Study of XXX in Treatment-Seeking Subjects With Opioid Use Disorder

A Twelve Week, Randomized, Double Blind, Placebo Controlled, Parallel Group, Dose Ranging Study with Follow Up Evaluating the Safety and Efficacy of XXX for Smoking Cessation in Healthy Adolescent Smokers

A Phase III, Multicenter, Open-label, 12-month Extension Safety and Tolerability Study of XXX in the Treatment of Adults with Binge Eating Disorder

Bipolar Disorder

A Multicenter, Open-label Trial to Evaluate the Safety and Tolerability of XXX in the Treatment of Subjects with Bipolar I Disorder

A Multicenter, Randomized, Double-blind Trial of XXX versus Placebo for the Acute Treatment of Subjects Manic Episodes, With or Without Mixed Features, Associated With Bipolar I Disorder

A Phase III, randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of XXX in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of XXX Monotherapy in the Treatment of Patients with Major Depressive Episodes Associated with Bipolar I or Bipolar II Disorder (Bipolar Depression)

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter, Fixed-dose Clinical Trial Evaluating the Efficacy, Safety and Tolerability of XXX in Patients with Bipolar I Depression

A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Evaluate the Efficacy and Safety of Once a Day, XXX for Sublingual Administrations (XXX Tablet) 0.1mg and 0.4mg as an Adjunctive Therapy in the Treatment of Acute Depressive Episodes Associated with Bipolar I Disorders in Adult Subjects

CLINICAL TRIAL EXPERIENCE (*continued*):

Depression

A Double-Blind, Placebo-Controlled, Fixed-Dose Study of XXX in Patients with Major Depressive Disorder

A Study of XXX Plus XXX in Treatment-Resistant Depression (TRD)

A Phase II/III, Randomized, Double-blind, Active-controlled Trial to Assess the Efficacy and Safety of XXX Administered Orally to Subjects with Treatment Resistant Major Depressive Disorder

A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive XXX in Major Depressive Disorder

An Open-Label, Single-Arm, Multicenter, Prospective, Phase IV, Interventional, Flexible Dose Study to Evaluate the Effectiveness of XXX on Goal Achievement After a Change in Antidepressant Medication for the Treatment of Subjects With Major Depressive Disorder - Goal Achievement After a Change to XXX in Adults With Major Depressive Disorder

An Phase III, Open-label, Long-term Safety Study of XXX as Adjunctive Therapy in Patients with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in the Prevention of Relapse in Patients with Major Depressive Disorder

A Phase III, Randomized, Double-blind, Placebo-controlled, Multicenter Study of XXX as Adjunctive Therapy in Major Depressive Disorder

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Intermittent Doses of XXX in the Treatment of Subjects with Severe Depression despite Antidepressant Treatment

A Phase III, Open-label Long-term Extension Safety Study of Intranasal XXX in Treatment-resistant Depression

A Phase III, 8-Week Prospective Randomized, Controlled, Single-Blind Trial of the XXX vs. Treatment-as-Usual to Evaluate Efficacy of Assay-Guided Treatment in Adults with Major Depressive Disorder

A Phase III, Non-Interventional Study of Subjects who have participated in XXX, A Study of Adjunctive Treatment of Major Depressive Disorder

A Phase II, Multicenter Double-Blind Placebo-Controlled Dose Finding Study of XXX in Patients with Major Depressive Disorder (MDD)

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase III, Randomized, Double-blind, Multicenter, Active-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Fixed Doses of Intranasal XXX Plus an Oral Antidepressant in Adult Subjects with Treatment-resistant Depression

A Phase II, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and tolerability of XXX as an adjunctive therapy in patients with major depressive disorder with an inadequate response to antidepressant treatment

A Phase III Efficacy and Safety Study of XXX for the Adjunctive Treatment of Major Depressive Disorder

A Phase III Multicenter Study of the Long-term Safety and Tolerability of XXX for the Adjunctive Treatment of Major Depressive Disorder in Adults who Have an Inadequate Response to Antidepressant Therapy

A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of XXX in the Adjunctive Treatment of Subjects with Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment

A Double-Blind, Placebo-Controlled, Randomized Add-On Study of XXX For Patients With Major Depressive Disorder (MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

Fibromyalgia

An Phase III Open-label Extension Study of XXX for 52 weeks in Pain Associated with Fibromyalgia

A Phase III, randomized, double-blind, double-dummy, placebo- and active-controlled, multi-center study of XXX in subjects with pain associated with fibromyalgia

Migraine

A Multicenter, Open Label, Long-Term Safety Study of XXX in Patients with Acute Migraines

A Phase III, Double-Blind, Randomized, Placebo Controlled, Safety, Efficacy, Trial of XXX for the Acute Treatment of Migraine

A Phase III, Multicenter, Randomized, Double-Blind, Placebo Controlled, Efficacy, Tolerability, and Safety Study of XXX in Episodic Migraine With or Without Aura

A Phase III, Open-label, Long-term, Safety Study of XXX (100 mg and 200 mg) in the Acute Treatment Of Migraine

CLINICAL TRIAL EXPERIENCE (continued):

A Phase III, Study of Three Doses of XXX (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine: A Randomized, Double-blind, Placebo-controlled Parallel Group Study

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine – the XXX 2 Study

A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase II Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of XXX Administered Intravenously in Patients with Chronic Migraine

Post-Traumatic Stress Disorder

A 40-Week Open-Label Extension Study to Evaluate XXX SL Taken Daily at Bedtime in Patients with PTSD

A Phase III, 12-Week Open-Label Extension Study to Evaluate XXX Taken Daily at Bedtime in Patients with PTSD

A Phase III, Double-Blind, Randomized, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX Taken Daily at Bedtime in Patients with Military-Related PTSD

Schizophrenia

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Risperidone Extended-Release Injectable Suspension XXX for Subcutaneous Use as Maintenance Treatment in Adult Patients with Schizophrenia

A Double-blind, Randomized, Active-controlled, Parallel-group Study of XXX 6-Month Formulation

A Phase III, Study to Assess the Long-Term Safety, Tolerability, and Durability of Treatment Effect of XXX in Subjects with Schizophrenia, Schizophreniform Disorder, or Bipolar I Disorder

A Phase IIb/III, Adaptive, Multi-center, Prospective, Randomized, Double-blind, Placebo-controlled Study of the Safety and Efficacy of XXX, a D-Amino Acid Oxidase Inhibitor, as an Add-on Treatment for Schizophrenia in Adults

Pilot study for Validation Test Plan XXX study

A Phase III, Open-Label, Multi-Center Trial to Assess the Safety and Effectiveness of XXX in Patients with Schizophrenia

CLINICAL TRIAL EXPERIENCE (*continued*):

A Phase IIb, Multicenter, Randomized, Double-blind, Parallel group, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of XXX as Adjunctive Treatment in Patients with Cognitive Impairment Associated with Schizophrenia Treated with Antipsychotics

A Phase III, 52-Week, Open-Label, Extension Study of XXX for the Adjunctive Treatment of Schizophrenia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of XXX as Adjunctive Treatment for the Negative Symptoms of Schizophrenia

A Phase III, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive XXX for the Treatment of Schizophrenia

A Fifteen-Month, Prospective, Randomized, Active-Controlled, Open-Label Flexible-Dose Study of XXX Compared with Oral Antipsychotic Treatment in Delaying Time to Treatment Failure in Adults with Schizophrenia who Have Been Incarcerated

A Phase III Study to Evaluate Weight Gain of XXX Compared to XXX in Adults with Schizophrenia

A Phase III, One Year, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of XXX as a Maintenance Treatment in Patients with Schizophrenia

XXX for Cannabis Use Disorder in Schizophrenia

A Phase II, multicenter, randomized, double blind, placebo-controlled study to assess the efficacy, safety and tolerability of XXX for the treatment of negative symptoms of schizophrenia

An Phase III, Open-Label, Long-Term Safety and Tolerability Study of XXX in the Treatment of Subjects With Schizophrenia

A Phase III, Multicenter, Extension of Study XXX to Assess the Long-term Safety and Durability of Effect of XXX in Subjects with Stable Schizophrenia

A Phase II, Randomized, Multicenter, Safety, Tolerability, and Dose-Ranging Study of XXX, a Component of XXX, in Adults with Schizophrenia Treated with XXX

A Randomized, Double-blind, Placebo-controlled, Parallel, 26-Week, Phase III Study of 2 Doses of an Alpha-7 Nicotinic Acetylcholine Receptor Agonist (XXX) or Placebo as an Adjunctive Pro-cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy

CLINICAL TRIAL EXPERIENCE (continued):

A Multicenter 26-Week Extension Study to Evaluate the Safety and Clinical Effects of Prolonged Exposure to 1 and 2 mg Doses of XXX, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist, as an Adjunctive Pro-cognitive Treatment in Subjects with Schizophrenia on Chronic Stable Atypical Antipsychotic Treatment

A Twelve Week, Randomized, Phase II, Double-blind, Parallel-Group Study of two Dose Levels of XXX Compared to Placebo in the Adjunctive Treatment Of Outpatients with Sub-Optimally controlled Symptoms of Schizophrenia

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of XXX (90 mg and 120 mg) as a Treatment in Subjects with Acute Schizophrenia Over 8 Weeks

Tardive Dyskinesia

A Phase III, Open-Label Rollover Study for Continuing XXX Administration for the Treatment of Tardive Dyskinesia

A Phase III, Open-Label, Safety and Tolerability Study of XXX for the Treatment of Tardive Dyskinesia

A Phase III, Randomized, Double-blind, Placebo-controlled, Parallel, Fixed-dose Study to Assess the Efficacy, Safety, and Tolerability of XXX for the Treatment of Tardive Dyskinesia

A Phase II, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy, Safety, And Pharmacokinetic Behavior of Orally Administered XXX in Subjects with Drug Induced Tardive Dyskinesia

Other Indications

A Phase II/III Randomized, Double-blind, Placebo-controlled trial of XXX in Subjects with Obsessive Compulsive Disorder

A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Subcutaneously Administered XXX in Premenopausal Women with Hypoactive Sexual Desire Disorder (HSDD) (with or without Decreased Arousal)

TEACHING EXPERIENCE:

2001 – Present Ongoing Teaching of UCSF Medical Residents, Attendings, and Nurse Practitioners Rotating at UCSF Substance Abuse program and DPH/IBIS Buprenorphine Induction Clinic

TEACHING EXPERIENCE (continued):

- 2003-2004 Clinical Supervisor, Pre-doctoral Intern, Clinical Psychology
UCSF Dept. of Psychiatry
- 2003 UCSF Surgery Interns & Residents, Management of Alcohol and Opiate
Withdrawal Symptoms Among Surgical Inpatients
- 2002-2005 UCSF Psychiatry Interns & Residents, Introduction to Substance Abuse and
Addiction Medicine
- 2002-2003 Teaching and Supervision of CPMC (California Pacific Medical Center)
Psychiatry Residents Rotation to Opioid Treatment Outpatient Program
- 1999 Instructor, Introductory to Clinical Medicine (ICM)
Harvard Medical School/ MIT Health Science Training MD/PhD Program
- 1998 Psychiatry Resident Supervisor at Harvard Medical School, Longwood
Program
- 1997 Psychiatry Resident Supervisor at Harvard Medical School, South Shore
Program

COMMITTEE ASSIGNMENTS:

- 2005 - 2006 Chairman, Medical Substance Abuse Committee
San Francisco General Hospital
- 2003 Group Leader, Buprenorphine Training
Office Based Treatment of Opiate Addiction
- 1997-1998 Training Committee Member, Brockton/W. Roxbury VAMC
- 1991 Secretary, Faculty of Medicine and Surgery
University of Santo Tomas, Manila, Philippines

FUNDED RESEARCH:

NIH/NIDA

Lead Physician, UCSF West Coast Node, California-Arizona Clinical Trials Network (CTN).
POATS – Prescription Opiate Addiction Treatment Study. National Study on Treatment of
prescription addicted patients using Buprenorphine.

The University of CA, San Francisco participated in the NIDA sponsored CTN cooperative
agreement.

PUBLICATIONS:

Pletcher MJ, Fernandez A, May TA, Westphal JR, Gamez CA, Hersh DF, Gonzales R. Unintended consequences of a quality improvement program designed to improved treatment of alcohol withdrawal in hospitalized patients. *Jt Comm J Qual Saf* 2005; 31(3): 148-157.

Chemali Z, Gamez C, Fricchione G. A Neonatal Case Report. Altered Mental Status in a Newborn of a Mother with Psychiatric Health Problems: The Role of Psychiatric Consultation. *Birth Issues* 2004;13(2):57-59.

PRESENTATIONS:

"A Dosing Review of Lorazepam Infusions in the Treatment of Severe Alcohol Withdrawal in a Transition Care Unit". Poster Presentation for the 12th Annual Meeting & Symposium, American Academy of Addictions Psychiatry, Amelia Island, FL, December 2001.

"Disorders of the Thinking Process", Advanced Psychopathology Course Seminar, West Roxbury VAMC, 1998.

Psychiatry Grand Rounds Chair, Case Presentation, Brockton/W. Roxbury VAMC, 1995.

"Use of Oral Rehydration Solutions in the Third World". Annual Interns' Paper Presentation, Santo Tomas University Hospital, 1992.

"Increasing the Yield of Tuberculosis Bacilli in the Sputum". Presented at the Second Annual Medical Seniors' Scientific Paper Presentation, University of Santo Tomas, 1991.